- Medicenna Therapeutics (TSX:MDNA) has revealed positive results of its bizaxofusp treatment to treat brain cancer
- Bizaxofusp has been shown to increase median overall survival by 88 per cent and improve overall survival at one and two years by 180 per cent and 290 per cent respectively
- As it currently stands there is no approved standard of care for recurrent glioblastoma, which is a fatal form of brain cancer
- Shares of Medicenna Therapeutics are down 6.67 per cent to C$2.66 as of 10:59 am ET
Medicenna Therapeutics (TSX:MDNA) has revealed positive results of its bizaxofusp treatment to treat brain cancer.
In a news release, the company stated that bizaxofusp has has been shown to increase the median overall survival of patients with recurrent glioblastoma (rGBM) by 88 per cent and improve overall survival at one and two years by 180 per cent and 290 per cent respectively.
As it currently stands, there is no approved standard of care for rGBM, which is a fatal form of brain cancer.
“These updated Phase 2b analyses reflect the planned design of a Phase 3 registration trial where patients with unresectable rGBM will be treated with bizaxofusp at the high dose irrespective of IL-4R expression,” Fahar Merchant, CEO of Medicenna Therapeutics, said in a statement.
Merchant explained the data is based on a larger pool of patients when compared with the company’s earlier results and indicated that an improvement in survival in the bizaxofusp arm was more significant when compared with a well-balanced EC arm.
Roughly 44 patients with rGBM were enrolled in the bizaxofsup study after surgery or radiotherapy and adjuvant therapy or other experimental therapies.
A separate study collected data from 81 unresectable rGBM patients who had received treatment with other therapies at clinical centres and was used to establish a matched EC arm.
Data was then used as a control arm versus survival data from the current phase 2 trial of bizaxofusp.
Thanks to the results, the company stated it is seeking partnership opportunities as well as a breakthrough therapy designation and a phase 3 trial design.
Formerly known as MDNA55, bizaxofusp is Medicenna’s IL-4 Empowered Superkine that has been studied in five clinical trials in more than 130 patients, including a Phase 2b trial in rGBM patients. Bizaxofusp has been granted FastTrack and Orphan Drug status from the U.S. Food and Drug Administration and European Medicines Agency, respectively.
Medicenna Therapeutics is a clinical-stage immunotherapy company focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases.
Shares of Medicenna Therapeutics Corp. (TSX:MDNA) are down 6.67 per cent to C$2.66 as of 10:59 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Medicenna Therapeutics Corp. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
